| HOME >> BIOLOGY >> TECHNOLOGY |
$ 1,572,341$ 1,344,999$ 4,579,215$ 3,979,648Other revenues
3,41510,11419,37536,375Total revenues
1,575,7561,355,1134,598,5904,016,023Cost of sales
917,365775,0562,679,8252,377,818Gross profit
658,391580,0571,918,7651,638,205Operating expenses:Research and development
70,84771,992218,651200,076Selling, general and administrative
319,389272,285913,604796,420Litigation settlements, net
2,2471,46228,45714,299Total operating expenses
392,483345,7391,160,7121,010,795Earnings from operations
265,908234,318758,053627,410Interest expense
85,77287,536254,836239,985Other (expense) income, net
12,073(15,269)22,543(29,437)Earnings before income taxes and noncontrolling interest
192,209131,513525,760357,988Income tax provision (benefit)
34,831(12,026)116,85133,245Net earnings
157,378143,539408,909324,743Net (earnings) loss attributable to the noncontrolling interest
(680)(356)(1,590)525Net earnings attributable to Mylan Inc. before preferred dividends
156,698143,183407,319325,268Preferred dividends (a)
-34,759-104,276Net earnings attributable to Mylan Inc. common shareholders
$
56,698$
8,424$
407,319$
220,992Earnings per common share attributable to Mylan Inc.common shareholders:Basic
$
.37$
.35$
.94$
.72Diluted
$
.36$
.33$
.92$
.71Weighted average common shares outstanding (a):Basic
426,412309,446432,265308,470Diluted
431,587437,921441,817313,014(a) The three and nine months ended September 30, 2011 includes the effect of the Preferred Stock Conversion into approximately 125.2 million shares of Mylan common stock on November 15, 2010. For the three months ended September 30, 2010, the if-converted method is dilutive; therefore, the preferred stock conversion is included in the computation of diluted earnings per share. For the nine
'/>"/>
| SOURCE Mylan Inc. Copyright©2010 PR Newswire. All rights reserved |